{"filings":[{"id":1194760,"accession_number":"0000718937-26-000029","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-06-22T20:05:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"STAAR Surgical shareholders approve equity plan amendment, increasing share reserve by 3.9M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 2 to Omnibus Equity Incentive Plan, adding 3.9M shares, total reserve now 26.705M.","Approved with 40.2M votes for, 0.97M against, and 0.07M abstentions.","All seven director nominees elected; BDO USA ratified as auditor; advisory say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945238,"accession_number":"0000718937-26-000027","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-06-09T20:02:15+00:00","items":["5.02"],"status":"ready","headline":"STAAR Surgical boosts Interim Co-CEO/CFO salary to $575k, bonus target to 60%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual base salary of Deborah Andrews (Interim Co-CEO and CFO) increased from $512,000 to $575,000.","Target annual cash bonus increased from 55% to 60% of base salary.","Compensation adjustments effective June 8, 2026, approved by Compensation Committee.","Adjustments reflect competitive market data and Andrews' contributions to strategic objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67841,"accession_number":"0000718937-26-000022","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-05-13T20:02:18+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q1 net sales up 119.6% to $93.5M; returns to profitability with GAAP EPS $0.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 net sales of $93.5M, up 119.6% YoY, driven by China recovery and U.S. growth.","GAAP net income $5.2M ($0.10 diluted EPS) vs net loss of $54.2M ($1.10 loss) a year ago.","Adjusted EBITDA $24.4M ($0.48/share) vs adjusted EBITDA loss of $26.3M in prior year.","Gross margin improved to 73.6% from 65.8%; operating expenses down 18% YoY.","China distributor inventory normalized; EVO+ ICL launch early demand exceeded expectations."],"consensus_eps_estimate":-0.065,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":93522000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98472,"accession_number":"0000718937-26-000009","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical prelim Q1 2026 net sales expected >$90M, up from $42.6M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales expected to exceed $90M in Q1 2026, more than double prior year's $42.6M.","China accounted for majority of increase; Americas delivered double-digit growth.","Significant cost-structure improvement expected to drive meaningful adjusted EBITDA increase.","Middle East & parts of EMEA/APAC saw sales decline due to geopolitical/macro headwinds.","Full Q1 results and 10-Q to be reported in early May; no forward guidance provided."],"consensus_eps_estimate":-0.065,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":93522000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113966,"accession_number":"0000718937-26-000005","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints interim co-CEOs; reports China stabilization, EVO+ launch, cost cuts","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Warren Foust and Deborah Andrews named Interim Co-CEOs after Alcon merger rejected by shareholders in Jan 2026.","Cost reductions beat $225M second-half 2025 run rate target; operating expenses lowered significantly.","China EVO ICL demand recovered at mid-single-digit rate in 2025; distributor inventories normalized.","EVO+ received China regulatory approval mid-2025; early demand exceeds expectations; shipments began Nov 2025.","FDA expanded EVO ICL age range to 21-60 in US, adding ~8M potential patients; new SVP hires in supply chain and APAC."],"consensus_eps_estimate":0.0583,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":239442000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113965,"accession_number":"0001193125-26-038534","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STAAR Surgical CLO Nathaniel Sisitsky departs; receives severance and consulting deal","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathaniel Sisitsky terminated as Chief Legal Officer and Corporate Secretary effective Feb 4, 2026; treated as termination without cause.","Severance includes 12 months base salary, 12 months insurance premium reimbursement, 2025 annual bonus, and $75,000 retention award installment.","Consulting agreement runs through March 13, 2026 at $8,000/week plus $10,000 completion fee for transition of legal function.","March 2026 RSUs accelerated and vested; all other equity awards (options, PSUs, other RSUs) forfeited as of Separation Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113964,"accession_number":"0001193125-26-032630","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints interim co-CEOs after CEO Farrell steps down; global CEO search launched","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen C. Farrell stepped down as CEO effective Jan 31, 2026, per prior cooperation agreement with Broadwood Partners.","Warren Foust (President/COO) and Deborah Andrews (CFO) named interim co-CEOs effective Feb 1, 2026.","Board's Search Committee launched global CEO search; internal and external candidates considered.","Foust and Andrews each awarded $375,000 in RSUs vesting Aug 1, 2026, for interim service.","Foust's letter agreement includes additional severance if not offered permanent CEO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113963,"accession_number":"0001193125-26-014681","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"STAAR Surgical elects new Board Chair; forms CEO Search Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neal C. Bradsher (Broadwood Capital, largest stockholder) elected Board Chair effective Jan 15, 2026.","Board creates Search Committee to identify CEO successor; chaired by Lilian Y. Zhou.","New Insight and Engagement Committee formed to gather business perspectives; chaired by Christopher M. Wang.","All directors determined independent; Audit Committee regains NASDAQ compliance.","Standing committee chairs: Audit (Zhou), Compensation (Silverman), Nominating & Governance (Bradsher)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113962,"accession_number":"0001193125-26-013622","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["1.01","3.01","5.02","8.01","9.01"],"status":"ready","headline":"STAAR Surgical CEO Farrell to step down Jan 31; Broadwood appoints three new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Stephen Farrell to step down as CEO by Jan 31, 2026; will remain as consultant for 1 year at $45k/month.","Board expands from 6 to 7; Neal Bradsher and Richard LeBuhn (Broadwood, 31% owner) and Christopher Wang (Yunqi Capital, 6.5%) appointed.","Elizabeth Yeu resigns as Board Chair and director; Board seeks new Chair and CEO.","NASDAQ audit committee noncompliance due to Yeu resignation; Company using cure period.","Cooperation agreement includes standstill until June 18, 2026; mutual non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113961,"accession_number":"0001193125-26-004699","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.02","5.07"],"status":"ready","headline":"STAAR Surgical's merger with Alcon terminated after shareholder vote; no fee","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger agreement with Alcon terminated effective Jan 6, 2026; no termination fee payable.","Special meeting held same day; 87.9% of shares represented (43,367,928 of 49,365,823).","Merger proposal not approved: 14,904,915 For, 27,339,877 Against, 1,123,136 abstain.","Compensation proposal not approved: 14,224,065 For, 27,905,792 Against, 1,238,071 abstain.","Both parties bear their own costs and expenses under the Merger Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113960,"accession_number":"0001193125-26-003534","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR Surgical shareholders vote down Alcon merger; deal terminated","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Preliminary vote tally failed to secure enough shareholder approval for the Alcon merger at special meeting on Jan 6, 2026.","STAAR will terminate the merger agreement with Alcon; no termination fee payable by either party.","Company remains standalone publicly traded (STAA); CEO Stephen Farrell highlights focus on EVO ICL technology and profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130375,"accession_number":"0001193125-25-311982","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alcon raises STAAR Surgical acquisition price to $30.75 per share from $28.00","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration increased to $30.75/share in cash, up from $28.00/share (approx. 9.8% increase).","Amendment treats RSUs and PSUs as Alcon equity awards; PSUs deemed earned at 100% of target.","Amendment eliminates 280G gross-up and related tax indemnification arrangements.","Deal requires stockholder approval and regulatory clearances; proxy statement filed September 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130374,"accession_number":"0001193125-25-310631","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR's go-shop period expires with no competing bids; 21 parties contacted, none submitted proposal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Go-shop period expired December 6, 2025; no competing acquisition proposals received.","STAAR engaged 21 third parties; two signed NDAs and received diligence, but no proposals.","Broadwood's claims of interest from Party A, B, C not substantiated; none signed NDAs.","Board says result validates process; Alcon is the right buyer for STAAR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130373,"accession_number":"0001193125-25-271708","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"STAAR Surgical amends Alcon merger: 30-day go-shop, no termination fee for qualified bidders, meeting postponed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["30-day go-shop period through Dec 6, 2025; STAAR may actively solicit third-party proposals.","No termination fee payable if STAAR terminates for a superior proposal from a qualified bidder.","Alcon waives matching rights and information rights during the go-shop period.","Special stockholder meeting postponed to Dec 19, 2025; record date remains Oct 24, 2025.","Alcon to engage STAAR stockholders and proxy advisors to solicit support for the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130372,"accession_number":"0001193125-25-266857","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical Q3 2025 earnings: press release content not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["The 8-K filing incorporates a press release by reference but no financial figures are included in the submitted text.","Investors should consult the full press release for specific revenue, EPS, and guidance details.","Confidence is low because the actual earnings data is not available for summarization.","The filing covers quarter ended September 26, 2025; date of report is November 5, 2025."],"consensus_eps_estimate":0.1647,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":181641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130371,"accession_number":"0001193125-25-250959","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR postpones special meeting on Alcon merger to Dec 3 amid ongoing discussions","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting of stockholders postponed from Nov 6 to Dec 3, 2025; new record date: Oct 24, 2025.","Postponement is in light of ongoing discussions with Alcon (NYSE: ALC) regarding the merger agreement.","Stockholders who held shares as of Oct 24 close are eligible to vote at the Dec 3 meeting.","Proxy solicitor Innisfree M&A available for questions; STAAR will send updated meeting materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130370,"accession_number":"0001193125-25-248797","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR adjourns special meeting on Alcon merger to Nov 6, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Special meeting scheduled for Oct 23, 2025 adjourned to 8:30 a.m. PT on Nov 6, 2025.","Record date for voting remains September 12, 2025; no other business conducted.","Shareholders with questions can contact Innisfree M&A Incorporated toll-free at 877-750-8233.","Alcon (ALC) and STAAR (STAA) agreed on the adjournment; no reason provided for delay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130369,"accession_number":"0001193125-25-243041","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical announces preliminary Q3 net sales $94.7M (+6.9%); includes $25.9M China shipment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary net sales $94.7M, up 6.9% YoY from $88.6M; outside China grew 7.7%.","$25.9M from December 2024 China ICL shipment recognized in Q3 upon payment receipt.","China distributors reduced inventory by ~$80-85M over nine months; new Q3 orders fell.","Distributor inventory at ~6 months as of Sep 26, aligned to contractual levels.","Special meeting Oct 23 to vote on Alcon merger proposal; early release for stockholders."],"consensus_eps_estimate":0.1647,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":181641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130368,"accession_number":"0001193125-25-238127","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"STAAR Surgical supplements proxy for Alcon merger; faces lawsuits, Broadwood opposition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two shareholder lawsuits filed Oct 1 in NY state court alleging proxy misrepresentations; demand letters also received.","STAAR voluntarily supplements proxy with additional disclosure; believes claims without merit but seeks to avoid delay.","Broadwood (27.3% holder) opposes merger; Soleus (6%) supports; Yunqi (5.1%) opposes. No competing proposals received.","Special meeting to vote on merger scheduled Oct 23, 2025; $28.00 per share consideration unchanged.","Citi's DCF analysis implied per share range $17.70-$37.50; selected precedent transactions EV/LTM revenue 3.1x-6.3x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146919,"accession_number":"0001193125-25-218827","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR urges stockholders to vote FOR Alcon merger at $28/sh, citing 59% VWAP premium","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alcon merger offers $28.00 per share cash; 51% premium to Aug 4 close, 59% to 90-day VWAP.","Second-largest active holder Soleus Capital (≈6% stake) supports merger and intends to vote FOR.","45-day window shop expired Sep 19; no competing acquisition proposals were received.","Board warns standalone stock would fall from $18.49 pre-announcement amid declining China sales and competition.","Broadwood's claims called flawed; STAAR ranks last in 2024-2027E net sales CAGR vs peer set."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146918,"accession_number":"0000950170-25-103974","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical announces Q2 2025 earnings; no specific figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["The 8-K filing references a press release but the exhibit text is not provided in the excerpt.","No revenue, EPS, or segment data are available from the filing body alone.","Investors should refer to the full press release for actual financial results."],"consensus_eps_estimate":-0.6743,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":86909000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146917,"accession_number":"0001193125-25-173090","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Alcon to acquire STAAR Surgical for $28/share in cash, ~$1.5B equity value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Alcon pays $28/share cash, a ~59% premium to STAAR's 90-day VWAP and 51% premium to Aug 4 close.","Transaction valued at ~$1.5B equity; Alcon will fund via short- and long-term credit facilities.","Expected to close in 6–12 months, subject to regulatory approvals and STAAR shareholder vote.","STAAR's board unanimously approved; deal is not subject to financing condition and expected to be accretive in year two.","STAAR will release Q2 results on Aug 6, 2025 but will not host a conference call due to pending acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165410,"accession_number":"0000950170-25-089733","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints Deborah Andrews permanent CFO, forms Capital Stewardship Committee, IR head leaves","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah Andrews appointed CFO effective June 25, 2025; she served as interim CFO since March 2025 and previously held the role from 2007-2013 and 2017-2020.","Compensation: base salary $495k, target bonus 55%, equity award valued at $1.4M (50% RSUs vesting over 3 years, 50% PSUs tied to revenue targets through 2027).","Company on track to achieve $225M annual SG&A run rate ahead of schedule.","Board forms new Capital Stewardship Committee chaired by Lilian Y. Zhou to guide capital allocation and oversight.","Brian Moore, VP Investor Relations and Corporate Development, will depart effective June 27, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165409,"accession_number":"0000950170-25-087967","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"STAAR Surgical annual meeting results: all six directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected: highest votes 42.1M (Farrell, Silverman), lowest 41.1M (Butcher); broker non-votes 2.5M each.","Ratification of BDO USA as auditor for FY2026: 44.5M for, 273k against, 10.5k abstain.","Non-binding advisory vote on NEO compensation approved: 41.1M for, 1.05M against, 24.7k abstain, 2.5M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165408,"accession_number":"0000950170-25-081391","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical posts investor presentation with no new material disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated June 4, 2025 reiterates STAAR as global leader in phakic IOLs.","Slides address the global myopia epidemic; no specific financial or guidance data provided.","Furnished under Regulation FD; not filed and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165407,"accession_number":"0000950170-25-073099","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized $30M share repurchase program, expected to run over six months from cash on hand.","Company had $222.8M cash and equivalents, no debt as of March 28, 2025; ~49.5M shares outstanding.","China's NMPA approved EVO+ Toric ICL for myopia correction (-0.5D to -18D, astigmatism ≤6D).","EVO+ spheric ICL application remains pending with NMPA; Switzerland manufacturing validations ongoing for China supply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165406,"accession_number":"0000950170-25-065607","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q1 revenue plunges 45%, swings to $54.2M loss; withdraws outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $42.6M, down 45% YoY; net loss $54.2M ($1.10) vs $3.3M loss prior year.","China revenue minimal as distributors consume inventory; ex-China sales up 9%.","Gross margin fell to 65.8% from 78.9% due to reduced production and Switzerland expansion costs.","Incurred $22.7M restructuring charges; targeting SG&A run rate cut to ~$225M.","Withdrew prior FY2025 outlook citing global economic uncertainty and tariff policy."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":42589000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165405,"accession_number":"0000950170-25-058173","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical board reshuffles; Silverman rejoins, Weisner exits, Jiang takes APAC strategy role with $1.275M RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Louis Silverman reappointed to board effective April 24, 2025; board expands to 7 members.","Director Aimee Weisner will not stand for re-election at June 2025 annual meeting; board to shrink to 6.","Wei Jiang becomes Chief of APAC Strategy under consulting agreement through fiscal 2025, receiving RSUs valued at $1.275M.","CEO cites China distribution challenges, pre-tariff inventory at distributors, consignment agreements, and Swiss production ramp-up.","Company emphasizes cost control and improving profitability; earnings call expected in May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183064,"accession_number":"0000950170-25-040620","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"STAAR Surgical realigns leadership: CFO steps down, new President & COO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Foust promoted to President & COO; Magda Michna named Chief Development Officer.","CFO Patrick Williams steps down at Board's request; severance of $575,000 plus 12-month consulting.","Deborah Andrews (former CFO) appointed Interim CFO; receives $150k/mo for Mar-May 2025.","CTO Keith Holliday retires at Board's request; severance of $550,110 plus 12-month benefits.","CEO Steve Farrell remains CEO; no longer holds President title."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183063,"accession_number":"0000950170-25-027880","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints Stephen Farrell CEO, replacing Tom Frinzi; Board chair changed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Farrell named President & CEO effective Feb 26, 2025, succeeding Thomas Frinzi at Board's request.","Farrell receives $725K base salary, 100% target bonus, 200K RSUs + 200K PSUs (0-200% target) sign-on equity.","Outgoing CEO Tom Frinzi gets 18 months severance and $45K/month consulting contract through Jan 2026.","Board elects Elizabeth Yeu as Chair; separates CEO & Chair roles; reduces Board from 7 to 6 members.","Lilian Zhou appointed Audit Committee Chair; Farrell resigns from committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183062,"accession_number":"0000950170-25-017872","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical announces Q4/FY2024 earnings; financial figures not provided in filing exhibits","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release (Ex-99.1) referenced but not included in submitted text; actual financial results unknown.","Slide presentation (Ex-99.2) contains only cover page and contact info, no financial data or outlook.","Earnings conference call scheduled for 5:00 p.m. ET on Feb 11, 2025, but details not available from filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":313901000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183061,"accession_number":"0000950170-25-004553","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical to report FY2024 earnings Feb 19; global ICL sales double-digit YoY except China","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Earnings release for Q4 and FY2024 set for Feb 19 after market close; conference call at 4:30pm ET.","CEO Frinzi states double-digit YoY ICL sales growth globally in FY2024, with the exception of China.","Persistent economic conditions and lower consumer confidence in China cited as headwinds for that market.","Chinese New Year period seen as key proxy for consumer demand; recent stimulus may inform FY2025 outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199641,"accession_number":"0000950170-24-119230","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K/A","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical reports Q3 net sales up 10% to $88.6M; revises 2024 regional growth assumptions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $10.0M ($0.20 EPS) vs $4.8M ($0.10 EPS) a year ago; adjusted EBITDA $16.2M.","ICL sales $89.1M, up 10%; gross margin 77.3% vs 79.2% on lower production absorption.","FY 2024 net sales outlook maintained at $340-345M; adjusted EBITDA ~$42M.","Americas EVO ICL growth revised to 17% (was 15%); U.S. to 20% (was 25%); EMEA to 10% (was 6%).","APAC growth cut to 5% (was 7%); China growth slashed to ~2% (was 10%); other APAC now 10-20% (was flat)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":264951000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199642,"accession_number":"0000950170-24-118953","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q3 net sales up 10% to $88.6M; FY China growth outlook halved to 2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $88.6M (+10% YoY); net income $10.0M ($0.20 EPS) vs $4.8M ($0.10) prior year.","Gross margin 77.3% vs 79.2% due to lower production absorption; operating income $5.7M (6.4% of sales).","Adjusted EBITDA $16.2M ($0.33) vs $16.5M ($0.33); maintained FY net sales outlook $340-345M.","China growth outlook cut to ~2% from 10%; APAC 4% (prior 7%), Americas raised to 17% (15%).","Cash $236.0M; management calls China softness transitory, cites potential policy stimulus."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":264951000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215658,"accession_number":"0000950170-24-092728","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q2 net sales $99.0M (record), EPS $0.15, raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 net sales of $99.0M (up 7% YoY); constant currency $100.4M (+9%).","Net income $7.4M ($0.15 diluted EPS) vs $6.1M ($0.12) YoY; Adjusted EBITDA $22.5M ($0.45).","Gross margin improved to 79.2% from 76.6% YoY, helped by cataract IOL reserve changes.","U.S. ICL sales $5.5M (+25% YoY, +10% sequentially); China ICL sales +3% YoY.","FY2024 net sales guidance raised to $340M-$345M (from $335M-$340M); Adjusted EBITDA ~$42M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":176361000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235046,"accession_number":"0000950170-24-076303","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"STAAR shareholders approve all four proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with FOR votes ranging from 40.1M to 40.9M shares.","Amendment to Omnibus Equity Plan approved: 39.1M FOR vs 1.8M AGAINST; adds 2.6M shares.","BDO USA, P.C. ratified as independent auditor for FY2024 with 40.0M FOR, 3.4M AGAINST.","Say-on-pay advisory vote passed with 34.0M FOR, 6.9M AGAINST; broker non-votes 2.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235045,"accession_number":"0000950170-24-072251","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical furnishes slide deck for June 12 investor presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will present to investors starting June 12, 2024; slide deck furnished as Exhibit 99.1.","No financial results, guidance, or operational updates were included in the filing body or available exhibit text.","Filing is a routine Regulation FD disclosure; no specific numbers, targets, or strategic changes cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235044,"accession_number":"0000950170-24-054454","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q1 net sales up 5% to $77.4M; net loss $0.07ps; raises FY24 EBITDA outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $77.4M (+5% YoY; +7% constant currency); ICL sales +9% on +2% units.","Net loss $3.3M ($0.07 loss per share) vs net income $2.7M ($0.05) a year ago; Adjusted EBITDA $5.3M ($0.11) vs $10.0M ($0.20).","U.S. sales $5M, up 15% YoY and 21% sequentially; record cash $252.1M.","FY2024 net sales outlook reiterated at $335-$340M; Adjusted EBITDA guidance raised to ~$39M ($0.75 per share) from ~$36M.","APAC sales +9% (China +10%); EMEA +11%; largest-ever U.S. practice commitment to EVO ICL announced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":77356000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235043,"accession_number":"0000950170-24-041613","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical preliminary Q1 net sales >$77M; record US ICL sales of $5M, up 20% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q1 2024 net sales in excess of $77M; US ICL sales hit record $5M, up ~20% sequentially.","EMEA ICL sales up ~11% YoY; APAC ICL sales up ~9% including ~10% growth in China.","Cash and investments ~$248M (Dec 2023: $232.4M); accounts receivable ~$70M (Dec 2023: $94.7M).","Fiscal 2024 net sales outlook now expected at higher end of $335M-$340M range.","Full Q1 results and 2024 outlook to be discussed on earnings call on/about May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":77356000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252869,"accession_number":"0000950170-24-032512","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"STAAR Surgical surpasses 3 million cumulative ICL sales globally","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["More than 3 million Implantable Collamer Lenses (ICLs) sold worldwide; EVO ICL accounts for ~2.5 million of that total.","CEO Tom Frinzi cites EVO ICL as next logical step in refractive innovation with clear patient outcome differentiators.","Milestone reflects growing adoption for myopia, astigmatism, and presbyopia correction via minimally invasive procedure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252868,"accession_number":"0000950170-24-029647","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints two new directors; board expands to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arthur Butcher (Boston Scientific EVP, MedSurg & APAC) and Wei Jiang (retired Bayer EVP) join board effective March 12, 2024.","Board increased from 6 to 8 directors; will reduce to 7 after K. Peony Yu's term ends in June 2024.","Butcher brings med-device marketing and APAC expertise; Jiang brings 25+ years pharma/device experience with China focus.","Director Yu will not stand for re-election at 2024 annual meeting; board thanks her for over 3 years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252867,"accession_number":"0000950170-24-022247","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical holds Q4/FY2023 earnings call; partial transcript provided, no specific results extractable.","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["STAAR Surgical held earnings call on 2/26/2024 for Q4 and FY2023 results; transcript furnished as Exhibit 99.1.","Participants included CEO Tom Frinzi and CFO Patrick Williams.","Analyst participants from Morgan Stanley, Canaccord Genuity, William Blair, Stephens, BTIG, Mizuho, Piper Sandler, Needham, Oppenheimer, Stifel, Sidoti.","Specific financial figures (EPS, revenue, guidance) are absent from the provided text; only call introduction is present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252866,"accession_number":"0000950170-24-020126","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical Q4 net sales up 19% to $76.3M; ICL sales +22%; FY2024 outlook $335-340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $76.3M (+19% YoY), ICL sales $74.6M (+22%), ICL units +19%.","Q4 net income $7.8M ($0.16 EPS) vs $6.8M ($0.14 EPS); gross margin 79.6% vs 77.7%.","FY2023 net sales $322.4M (+13%), net income $21.3M ($0.43 EPS) vs $39.7M ($0.80 EPS).","Cash, cash equivalents and investments $232.4M, no debt; FY2024 net sales outlook $335-340M.","China ICL sales grew 30% in Q4; EMEA up 18%; company affirms FY2024 sales outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":322415000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252865,"accession_number":"0000950170-24-002738","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical prelim Q4 net sales ~$76.5M, ICL sales +22%; FY2024 outlook $335-340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2023 net sales ~$322.5M (+13% YoY); Q4 net sales ~$76.5M (+19% YoY).","Global ICL sales up 22% in Q4 (APAC +26%) and 18% for FY2023; ICL unit growth outpaced refractive industry by 26 points in 2023.","FY2024 net sales guidance of $335-340M, implying ~10% ICL growth in both China and U.S.; GAAP operating margin expected at least breakeven.","Cash and investments ~$230M, up ~$28M from Q3; accounts receivable ~$90M.","Full FY2023 results to be reported on or about Feb 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":322415000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270360,"accession_number":"0000950170-23-067757","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"STAAR Surgical appoints Lillian Zhou to board; Dr. Gil Kliman resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lillian Zhou appointed to Board of Directors effective December 4, 2023.","Zhou brings 20+ years of capital markets experience; founded Yulan Capital Management.","Gilbert Kliman, M.D. resigned effective December 1, 2023; no disagreement cited.","Zhou replaces Kliman as a board member; other directors include Stephen Farrell, Tom Frinzi, Aimee Weisner, Elizabeth Yeu, K. Peony Yu."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270359,"accession_number":"0000950170-23-064344","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical announces investor presentations starting Nov 16, 2023; slide content not provided in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company to give investor presentations starting November 16, 2023.","Slide presentation attached as Exhibit 99.1 but no substantive data included in the filing text.","No financial results, guidance, or material updates disclosed in the 8-K.","Filing is procedural under Regulation FD for investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270358,"accession_number":"0000950170-23-058298","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical Q3 2023 earnings call transcript furnished; exhibit incomplete","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing includes transcript of November 1, 2023 conference call for quarter ended September 29, 2023.","Transcript provided is partial (introductory remarks only); financial results not included in this 8-K.","No specific EPS, revenue, or guidance figures available from the furnished exhibit.","Press release of Q3 results was issued separately before the call; this filing is procedural."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":246142000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270357,"accession_number":"0000950170-23-057446","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"STAAR Surgical reports Q3 2023 results; exhibit not included in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release furnished as Exhibit 99.1 for quarter ended September 29, 2023.","Specific financial figures (revenue, EPS, guidance) not available in the provided 8-K text.","No details on segment performance or outlook could be extracted."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":246142000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287317,"accession_number":"0000950170-23-048877","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K/A","filed_at":"2023-09-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical amends Investor Day slide: 2026E Adj. EBITDA ex. SBC range raised to $90M-$120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adjusted EBITDA ex. SBC for 2026E corrected to $90M-$120M from previously stated $75M-$110M.","CapEx expected ~$20-$30M annually; 2026E free cash flow estimated at $75-$110M.","Clarification relates solely to slide 108 of the September 14, 2023 Investor Day presentation.","No other projections or statements from the original 8-K were amended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287321,"accession_number":"0000950170-23-048170","cik":718937,"company_name":"STAAR SURGICAL CO","ticker":"STAA","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STAAR Surgical holds Investor Day; presents long-term Vision 2026 plan","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day held on September 14, 2023, with presentations by CEO Tom Frinzi and CFO Patrick Williams.","Agenda includes extending EVO ICL leadership, China growth, and surgeon panel on global EVO ICL experience.","No specific financial guidance or operational targets disclosed in the furnished slide presentation.","Event focused on long-term growth strategy and value creation through Vision 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1498135872.9757884,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-09-14T23:59:59+00:00|287321"}